Eli Lilly and Company (LLY)
Why Eli Lilly, Viking Therapeutics, and Novo Nordisk Stocks All Popped Friday
Positive jobs news and positive rumors out of China are lifting stock markets today, as the U.S. Labor Department reports adjusted nonfarm payrolls grew by 177,000 jobs in April, and CNBC reports that China may be "evaluating the possibility of starting trade negotiations" that could abbreviate a trade war with the U.S.
Eli Lilly and Company (LLY) Q1 2025 Earnings Call Transcript
Eli Lilly and Company (NYSE:LLY ) Q1 2025 Results Conference Call May 1, 2025 10:00 AM ET Company Participants Mike Czapar - Senior Vice President of Investor Relations Dave Ricks - Chair and CEO Lucas Montarce - Chief Financial Officer Dan Skovronsky - Chief Scientific Officer & President of Lilly Immunology Patrik Jonsson - President of Lilly Cardiometabolic Health & Lilly USA Anne White - President of Lilly Neuroscience Ilya Yuffa - President of Lilly International Jake Van Naarden - President of Lilly Oncology Marc Kemen - Investor Relations Wes Taul - Investor Relations Wai Wong - Investor Relations Conference Call Participants Asad Haider - Goldman Sachs Geoff Meacham - Citibank Chris Schott - JPMorgan Terence Flynn - Morgan Stanley Mohit Bansal - Wells Fargo Alex Hammond - Wolfe Seamus Fernandez - Guggenheim Tim Anderson - Bank of America Evan Seigerman - BMO Capital Markets James Shin - Deutsche Bank Umer Raffat - Evercore Steve Scala - TD Cowen Courtney Breen - Bernstein David Risinger - Leerink Partners Kerry Holford - Berenberg Akash Tewari - Jefferies Trung Huynh - UBS Carter Gould - Cantor Rajesh Kumar - HSBC Kripa Devarakonda - Truist Securities Operator Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q1 2025 Earnings Conference Call. At this time, all participants are in a listen-only mode.
LLY's Q1 Earnings Miss, Mounjaro & Zepbound Drive Sales, Stock Down
Eli Lilly misses first-quarter estimates for earnings but beats the same for sales. Mounjaro and Zepbound sales beat estimates.
Jobless Claims Higher; Q1 Earnings from LLY, MCD & More
Last week, 241K Americans filed for unemployment on Initial Jobless Claims, with Continuing Claims touching 1.9 million.
Here's What Key Metrics Tell Us About Lilly (LLY) Q1 Earnings
The headline numbers for Lilly (LLY) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Eli Lilly shares slide despite weight-loss drug boost as company trims 2025 profit outlook
Eli Lilly and Co (NYSE:LLY) shares fell as much as 7.7% at the open on Thursday after the drugmaker cut its 2025 profit forecast, overshadowing booming sales of its blockbuster weight-loss drugs. The pharmaceutical giant reported a 45% year-over-year jump in first-quarter revenue to $12.73 billion, slightly above Wall Street expectations, driven by surging demand for its GLP-1 drugs Mounjaro and Zepbound.
Eli Lilly (LLY) Q1 Earnings Lag Estimates
Eli Lilly (LLY) came out with quarterly earnings of $3.34 per share, missing the Zacks Consensus Estimate of $3.52 per share. This compares to earnings of $2.58 per share a year ago.
Eli Lilly Revenue Up on Demand for Mounjaro, Other Weight-Loss Meds
Eli Lilly revenue surged in the latest quarter on steady sales of Mounjaro and other weight-loss treatments in its portfolio.
Eli Lilly Stock Slips as Lowered Profit Outlook Outweighs Solid Q1 Results
Shares of Eli Lilly (LLY) fell in premarket trading Thursday after the pharmaceutical giant's lowered profit projections outweighed first-quarter results that came in above analysts' expectations.
Eli Lilly sales soar 45% on weight loss drug demand, but drugmaker cuts profit outlook after cancer treatment deal
Eli Lilly topped first-quarter earnings and revenue estimates. The drugmaker said sales of weight loss drug Zepbound and diabetes treatment Mounjaro spiked in the first quarter.
Eli Lilly's Stock Is Up 15% This Year, and Here's Why It Could Take Off Even More
Growth stocks often don't come cheap, especially when their prospects look great, as is the case with Eli Lilly (LLY 1.09%). It is the most valuable healthcare company in the world, with a market cap of around $800 billion.
Eli Lilly: Why Orforglipron Matters, A Lot
Eli Lilly and Company's orforglipron generated positive results in the phase 3 trial in type 2 diabetes patients. The results look good or better than oral semaglutide (across trials) and similar to injectable semaglutide. The importance of these LLY results cannot be understated, as this should be the first oral obesity product that can be produced at scale to satisfy global demand.
